Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.Mathias Rummel, A. Banat, Ulrich von Gruenhagen et al.|Journal of Clinical Oncology|2012Cited by 39
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)Mathias Rummel, Richard Greil, Christian Buske et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 6